

Resource Summary Report

Generated by [SPARC SAWG](#) on Sep 16, 2026

MUGA

RRID:SCR_014072

Type: Tool

Proper Citation

MUGA (RRID:SCR_014072)

Resource Information

URL: <http://csbio.unc.edu/CCstatus/index.py?run=Geneseek>

Proper Citation: MUGA (RRID:SCR_014072)

Description: MUGA genotypes for 458 samples from the developing CC lines described in the February 2012 issue of Genetics. Genotypes for 168 reference strains that include biological and technical replicates for the the 8 CC founder strains and their F1 crosses are also provided. Genotype calls are those reported by Illumina. All results are provided as comma separated files with one row per marker. Each marker is identified by a probe name and its genomic position in NCBI Build 37.

Resource Type: data or information resource, data set

Defining Citation: [PMID:22345608](#)

Keywords: genetic, genotype, reference strain, cc line

Resource Name: MUGA

Resource ID: SCR_014072

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260912T200347+0000

Ratings and Alerts

No rating or validation information has been found for MUGA.

No alerts have been found for MUGA.

Data and Source Information

Usage and Citation Metrics

We found 267 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Williams EC, et al. (2026) Expression of endogenous retroviral elements is associated with extracellular matrix remodeling in prostate cancer. *Mobile DNA*, 17(1), 1.

Mullis MN, et al. (2026) Genetic correlation-guided mega-analysis of DO mice provides mechanistic insight and candidate genes for age-related pathologies. *PLoS genetics*, 22(2), e1012037.

DiPersio JF, et al. (2026) CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial. *Nature medicine*, 32(5), 1763.

Seth S, et al. (2026) The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer. *Breast cancer research : BCR*, 28(1).

Walters MC, et al. (2025) Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. *Blood advances*, 9(5), 955.

Preusser M, et al. (2025) Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. *Nature medicine*, 31(8), 2797.

Sobrinho S, et al. (2025) Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease. *Nature communications*, 16(1), 3137.

Arora A, et al. (2025) A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). *Trials*, 26(1), 73.

Shortreed H, et al. (2025) Evaluating the Necessity and Impact of Cardiac Imaging on Breast Cancer Care in Northwestern Ontario. *Cancers*, 17(12).

Schoenrock SA, et al. (2025) Genetic mapping in collaborative cross mouse strains identifies loci that affect initial sensitivity to cocaine. *Psychopharmacology*.

Maio M, et al. (2025) First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. *Journal for immunotherapy of cancer*, 13(8).

Cascone T, et al. (2025) Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. *Nature medicine*, 31(8), 2788.

Nasca V, et al. (2025) Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial. BMC cancer, 25(1), 633.

Torrado J, et al. (2025) Prevalence of frequent premature ventricular contractions and left-ventricular systolic dysfunction in patients receiving Holter monitoring. Journal of cardiovascular electrophysiology, 36(1), 54.

Levytska K, et al. (2025) Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies. Gynecologic oncology reports, 58, 101727.

Vaynrub A, et al. (2024) Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer. Cardio-oncology (London, England), 10(1), 68.

Bao KK, et al. (2024) Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Breast (Edinburgh, Scotland), 73, 103612.

Builoff V, et al. (2024) Evaluating AI Proficiency in Nuclear Cardiology: Large Language Models take on the Board Preparation Exam. medRxiv : the preprint server for health sciences.

Ghobadi A, et al. (2024) Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. Research square.

Kilburn LB, et al. (2024) The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nature medicine, 30(1), 207.